My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search
Bajaj Finance hits record high
Jul 11,2016

The announcement was made during market hours today, 11 July 2016.

Meanwhile, the S&P BSE Sensex was up 488.64 points or 1.8% at 27,615.54.

On BSE, so far 29,000 shares were traded in the counter as against average daily volume of 6,585 shares in the past one quarter. The stock hit a high of Rs 8,703 so far during the day, which is a record high for the counter. The stock hit a low of Rs 8,200 so far during the day. The stock had hit a 52-week low of Rs 4,678 on 23 September 2015. The stock had outperformed the market over the past one month till 8 July 2016, surging 5.46% compared with Sensexs 0.39% rise. The scrip had also outperformed the market in past one quarter, advancing 15.08% as against Sensexs 9.94% rise.

The large-cap company has equity capital of Rs 53.87 crore. Face value per share is Rs 10.

Bajaj Finances net profit rose 36.4% to Rs 315.04 crore on 35.5% growth in total income to Rs 1957.45 crore in Q4 March 2016 over Q4 March 2015.

Bajaj Finance is a diversified non-banking financial company.

Powered by Capital Market - Live News

PFC spurts about 8% in two sessions
Jul 11,2016

Meanwhile, the BSE Sensex was up 487.66 points, or 1.80%, to 27,614.56.

On BSE, so far 6.24 lakh shares were traded in the counter, compared with average daily volume of 1.78 lakh shares in the past one quarter. The stock hit a high of Rs 203.50 and a low of Rs 195.70 so far during the day. The stock hit a 52-week high of Rs 270.60 on 21 July 2015. The stock hit a 52-week low of Rs 140.40 on 17 February 2016. The stock had outperformed the market over the past 30 days till 8 July 2016, rising 17.70% compared with 1.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 15.33% as against Sensexs 9.94% rise.

The large-cap company has an equity capital of Rs 1320.04 crore. Face value per share is Rs 10.

Power Finance Corporation (PFC) announced during trading hours on Friday, 8 July 2016, that its board will meet on 14 July 2016 to consider issue of bonus shares.

Shares of PFC rose 3.55% to Rs 194.15 on Friday, 8 July 2016. The stock has risen 7.89% in two sessions from its close of Rs 187.50 on 7 July 2016.

PFCs net profit declined 19.29% to Rs 1259.65 crore on 5.7% growth in total income to Rs 6786.99 crore in Q4 March 2016 over Q4 March 2015.

State-run PFCs main business is to provide finance to the power sector. Government of India (GoI) currently holds 67.8% stake in PFC (as per the shareholding pattern as on 31 March 2016).

Powered by Capital Market - Live News

Cadila Healthcare jumps after USFDA approval for anti-diabetic drug
Jul 11,2016

The company made the announcement during trading hours today, 11 July 2016.

Meanwhile, the BSE Sensex was up 467.64 points, or 1.72%, to 27,594.54.

On BSE, so far 1.69 lakh shares were traded in the counter, compared with average daily volume of 86,208 shares in the past one quarter. The stock hit a high of Rs 374.55 and a low of Rs 365.50 so far during the day. The stock hit a record high of Rs 454.40 on 23 October 2015. The stock hit a 52-week low of Rs 295.50 on 18 January 2016. The stock had outperformed the market over the past 30 days till 8 July 2016, rising 12.79% compared with 1.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 12.05% as against Sensexs 9.94% rise.

The large-cap company has an equity capital of Rs 102.37 crore. Face value per share is Re 1.

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Nateglinide Tablets USP in strengths of 60 milligram (mg) and 120 mg.

The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus. It will be produced at the groups formulations manufacturing facility at the pharma special economic zone (SEZ) in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in the financial year ended 2003-2004.

Cadila Healthcares consolidated net profit rose 10.9% to Rs 388.70 crore on 5.7% growth in net sales to Rs 2375.50 crore in Q4 March 2016 over Q4 March 2015.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Bharti Airtel gains after completing acquisition of spectrum from Aircel
Jul 11,2016

The announcement was made yesterday, 10 July 2016.

Meanwhile, the S&P BSE Sensex was up 462.38 points or 1.7% at 27,589.28.

The stock gained on heavy volumes. On BSE, so far 10.65 lakh shares were traded in the counter as against average daily volume of 1.97 lakh shares in the past one quarter. The stock hit a high of Rs 367.35 and a low of Rs 359.10 so far during the day. The stock had hit a 52-week high of Rs 452.45 on 21 July 2015. The stock had hit a 52-week low of Rs 282.30 on 29 January 2016. The stock had outperformed the market over the past one month till 8 July 2016, gaining 0.74% compared with Sensexs 0.39% rise. The scrip had also outperformed the market in past one quarter, advancing 6.19% as against Sensexs 9.94% rise.

The large-cap company has equity capital of Rs 1998.70 crore. Face value per share is Rs 5.

Bharti Airtel announced that the spectrum trading deal for the acquisition of 20 MHz 2300 Band 4G TD spectrum from Aircel was successfully concluded for 6 out of 8 circles barring Andhra Pradesh and Orissa. Bharti Airtel said it will update the exchanges when the transactions for the remaining circles of Andhra Pradesh and Orissa are completed.

Bharti Airtels consolidated net profit rose 2.8% to Rs 1290.30 crore on 8.4% growth in net sales to Rs 24959.60 crore in Q4 March 2016 over Q4 March 2015.

Bharti Airtel ranks amongst the top three mobile service providers globally in terms of subscribers. The company has its operations in 20 countries across Asia and Africa.

Powered by Capital Market - Live News

Tata Motors surges after reporting robust wholesales in June
Jul 11,2016

The company announced the sales volume data after market hours on Friday, 8 July 2016.

Meanwhile, the S&P BSE Sensex was up 451.16 points or 1.66% at 27,578.06.

On BSE, so far 5.46 lakh shares were traded in the counter as against average daily volume of 8.47 lakh shares in the past one quarter. The stock hit a high of Rs 486.40 and a low of Rs 471.10 so far during the day. The stock had hit a 52-week high of Rs 489.60 on 23 June 2016. The stock had hit a 52-week low of Rs 266 on 11 February 2016. The stock had underperformed the market over the past one month till 8 July 2016, falling 0.24% compared with Sensexs 0.39% rise. The scrip had, however, outperformed the market in past one quarter, advancing 24.99% as against Sensexs 9.94% rise.

The large-cap company has equity capital of Rs 577.44 crore. Face value per share is Rs 2.

Global wholesales of all Tata Motors commercial vehicles and Tata Daewoo range rose 5% to 32,720 units in June 2016 over June 2015. Global wholesales of all passenger vehicles surged 31% to 59,831 units in June 2016 over June 2015.

Tata Motors consolidated net profit jumped 201.6% to Rs 5177.06 crore on 18.8% growth in net sales to Rs 79926.12 crore in Q4 March 2016 over Q4 March 2015.

Tata Motors is a market leader in commercial vehicles in India. The companys British unit JLR sells premium luxury cars.

Powered by Capital Market - Live News

Dishman Pharma jumps after USFDA concludes inspection of Gujarat facility
Jul 11,2016

Meanwhile, the BSE Sensex was up 461.75 points, or 1.70%, to 27,588.65.

On BSE, so far 2.36 lakh shares were traded in the counter, compared with average daily volume of 1.56 lakh shares in the past one quarter. The stock hit a high of Rs 149 and a low of Rs 141.55 so far during the day. The stock hit a 52-week high of Rs 209.85 on 4 November 2015. The stock hit a 52-week low of Rs 79.78 on 20 July 2015. The stock had underperformed the market over the past 30 days till 8 July 2016, falling 9.63% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, sliding 18.27% as against Sensexs 9.94% rise.

The small-cap company has an equity capital of Rs 32.28 crore. Face value per share is Rs 2.

Dishman Pharmaceuticals and Chemicals announced on Saturday, 9 July 2016, that renewal of US Food and Drug Administration (USFDA) inspection of the companys Bavla facility in Ahmedabad, Gujarat has been successfully completed on 8 July 2016.

The Bavla manufacturing facility plant has a state-of-the-art research and development (R&D) centre with 200 scientists focused on process development and industrialisation, working in continuous three shift, 6-day R&D operations.

On a consolidated basis, net profit of Dishman Pharmaceuticals and Chemicals rose 29.29% to Rs 49.92 crore on 3.55% decline in net sales to Rs 405.67 crore in Q4 March 2016 over Q4 March 2015.

Dishman Pharmaceuticals and Chemicals is the global outsourcing partner for the pharmaceutical industry offering a portfolio of development, scale-up and manufacturing services. The products and services offered by the company spans from chemical development to commercial manufacture and supply of active pharmaceutical ingredients.

Powered by Capital Market - Live News

New order boosts Nila Infra
Jul 11,2016

The announcement was made after market hours on Friday, 8 July 2016.

Meanwhile, the S&P BSE Sensex was up 471.85 points or 1.74% at 27,598.75.

On BSE, so far 1.93 lakh shares were traded in the counter as against average daily volume of 1.13 lakh shares in the past one quarter. The stock hit a high of Rs 14.90 and a low of Rs 14.11 so far during the day. The stock had hit a record high of Rs 19.85 on 28 December 2015. The stock had hit a 52-week low of Rs 7.80 on 10 September 2015. The stock had outperformed the market over the past one month till 8 July 2016, surging 13.83% compared with Sensexs 0.39% rise. The scrip had also outperformed the market in past one quarter, advancing 8.67% as against Sensexs 9.94% rise.

The small-cap company has equity capital of Rs 39.27 crore. Face value per share is Rs 1.

The work order is for the Integrated Slum In-situ Development for P.P.P. Project (Phase-II) of about 80 residential units at Ahmedabad under Urban Development & Urban Housing Development, Government of Gujarats Slum Rehabilitation and Redevelopment Policy-2013. The project envisages to rehabilitate about 80 slum-dwelling families living at Sabarmati, Kailashnagar, Ahmedabad. The total area under the project is about 4,166 sq. meters. The project will be redeveloped in 18 months at a total development cost of about Rs 6.80 crore. As consideration, Nila Infrastructures will get the balance vacant land admeasuring about 2,793 sq. meters on additional payment of an estimated premium of Rs 1.01 crore, the company said in a statement.

Nila Infrastructures net profit rose 17.6% to Rs 5.80 crore on 85.1% growth in net sales to Rs 69.30 crore in Q4 March 2016 over Q4 March 2015.

Nila Infrastructures is an established player in developing civic urban infrastructure projects on engineering, procurement and construction (EPC), turnkey, public-private partnership (PPP) mode as well as private white lable construction and industrial infrastructure projects.

Powered by Capital Market - Live News

United Spirits gains after conclusion of additional inquiry
Jul 11,2016

The announcement was made on Saturday, 9 July 2016.

Meanwhile, the BSE Sensex was up 480.01 points, or 1.77%, to 27,606.91.

On BSE, so far 11,000 shares were traded in the counter, compared with average daily volume of 35,482 shares in the past one quarter. The stock hit a high of Rs 2,645.35 and a low of Rs 2,592.30 so far during the day. The stock hit a 52-week high of Rs 3,837.50 on 29 July 2015. The stock hit a 52-week low of Rs 2,232 on 18 February 2016. The stock had outperformed the market over the past 30 days till 8 July 2016, rising 6.77% compared with 1.36% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 11.43% as against Sensexs 9.94% rise.

The large-cap company has an equity capital of Rs 145.33 crore. Face value per share is Rs 10.

United Spirits (USL) said that almost all the amounts identified in an additional inquiry into historical transactions concerning USL and its subsidiaries have been already provided for or expensed in the financial statements of USL or its subsidiaries for prior periods. USL said additional enquiries revealed fund diversions and improper transactions amounting to a total Rs 1225.30 crore in USLs books for the period from October 2010 to July 2014. After a mutually agreed transaction, Diageo gained control of United Spirits from Vijay Mallyas UB Group in July 2013. USL said that the companys management has recommended to the companys board of directors for USL to make a further provision of Rs 21.70 crore for the value of certain improper transactions identified by the additional inquiry which have not been previously expensed or provided for in USLs books.

United Spirits reported net loss of Rs 8.99 crore in Q4 March 2016 as against net loss of Rs 1799.28 crore in Q4 March 2015. Net sales rose 13.03% to Rs 2283.64 crore in Q4 March 2016 over Q4 March 2015.

United Spirits makes alcoholic beverages. It is a subsidiary of British multinational Diageo plc. Relay B.V., an indirect wholly- owned subsidiary of Diageo Plc holds 54.78% stake in United Spirits (as per the shareholding pattern as on 31 March 2016).

Powered by Capital Market - Live News

L&T moves higher on commencement of L&T Infotech IPO
Jul 11,2016

Meanwhile, the S&P BSE Sensex was up 450.19 points or 1.66% at 27,577.09.

On BSE, so far 34,000 shares were traded in the counter as against average daily volume of 2.07 lakh shares in the past one quarter. The stock hit a high of Rs 1,570 and a low of Rs 1,552.30 so far during the day. The stock had hit a 52-week high of Rs 1,886.25 on 17 July 2015. The stock had hit a 52-week low of Rs 1,016.60 on 12 February 2016. The stock had outperformed the market over the past one month till 8 July 2016, gaining 1.4% compared with Sensexs 0.39% rise. The scrip had also outperformed the market in past one quarter, advancing 28.65% as against Sensexs 9.94% rise.

The large-cap company has equity capital of Rs 186.40 crore. Face value per share is Rs 2.

Larsen & Toubro Infotechs (L&T Infotech) promoter L&T is selling a part of its stake through the IPO of L&T Infotech. L&T Infotech will not get any funds from the IPO and the entire sale proceeds will go to parent L&T. L&T is selling 1.75 crore shares of L&T Infotech through the IPO. The price band for the IPO has been fixed at Rs 705-710 per share. The bidding for the IPO closes on Wednesday, 13 July 2016.

L&T Infotech has raised Rs 372.75 crore from selling 52.5 lakh shares to a slew of anchor investors, including mutual funds, insurance companies, banks and foreign institutional investors (FIIs) ahead of the companys initial public offer (IPO). The issue of shares to anchor investors has been priced at Rs 710 per share -- the top end of the Rs 705-710 per share price band for the IPO. Foreign fund Auburn Limited is the biggest anchor investor in the L&T Infotech IPO. It has been allotted 22.53 lakh shares constituting almost 43% of the anchor investors portion.

HDFC Mutual Fund is the second biggest anchor investor in the IPO. It has been allotted 5.63 lakh shares. Among other major anchor investors, foreign fund FIL Investments (Mauritius) and New India Assurance Company have been allotted 2.81 lakh shares each. Prudential ICICI Technology Fund has been allotted 2.11 lakh shares. L&T Infotech has got a total of 22 anchor investors.

L&Ts consolidated net profit rose 18.6% to Rs 2453.64 crore on 18.51% rise in net sales to Rs 32812.24 crore in Q4 March 2016 over Q4 March 2015.

L&T is a major Indian multinational engaged in technology, engineering, construction, manufacturing and financial services. It operates in more than 30 countries worldwide.

Powered by Capital Market - Live News

Tata Steel gains on entering discussions for European businesses
Jul 11,2016

The announcement was made after trading hours on Friday, 8 July 2016.

Meanwhile, the BSE Sensex was up 450.31 points, or 1.66%, to 27,577.21.

On BSE, so far 1.31 lakh shares were traded in the counter, compared with average daily volume of 9.35 lakh shares in the past one quarter. The stock hit a high of Rs 325 and a low of Rs 320.50 so far during the day. The stock hit a 52-week high of Rs 364.15 on 21 April 2016. The stock hit a 52-week low of Rs 200 on 29 September 2015. The stock had underperformed the market over the past 30 days till 8 July 2016, sliding 6.86% compared with 1.36% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 1.13% as against Sensexs 9.94% rise.

The large-cap company has an equity capital of Rs 971.22 crore. Face value per share is Rs 10.

Tata Steel announced that it has entered into discussions with strategic players in the steel industry, including Thyssenkrupp AG for a strategic collaboration for its European businesses. The decision has been taken as an alternative to the ongoing process for the divestment of loss making Tata Steel UK. Tata Steel said that the discussions for strategic collaboration are currently at preliminary stage and there is no certainty of a transaction as the outcome depends on consultation and negotiations with various stakeholders. Tata Steel also said it would begin separate processes for the sale of its South Yorkshire specialty steels business and the Hartlepool pipe mills, excluding the 20-inch tube mill, in the UK. Tata Steel has already received interest from several bidders for these two businesses and the formal process for the sale of the businesses will commence shortly.

Tata Steel reported consolidated net loss of Rs 3213.76 crore in Q4 March 2016, higher than net loss of Rs 5674.29 crore in Q4 March 2015. Tata Steels total income fell 12.34% to Rs 29636.69 crore in Q4 March 2016 over Q4 March 2015.

Tata Steel is Europes second largest steel producer, with steelmaking in the UK and Netherlands, and manufacturing plants across Europe. The combined Tata Steel group is one of the worlds largest steel producers, with a steel capacity of more than 28 million tonnes and 80,000 employees across five continents.

Powered by Capital Market - Live News

PNB gains as RBI lifts restrictions on foreign purchases
Jul 11,2016

Meanwhile, the S&P BSE Sensex was up 400.65 points or 1.48% at 27,527.55.

On BSE, so far 3.32 lakh shares were traded in the counter as against average daily volume of 14.85 lakh shares in the past one quarter. The stock hit a high of Rs 122.05 and a low of Rs 119.90 so far during the day. The stock had hit a 52-week high of Rs 180.50 on 17 August 2015. The stock had hit a 52-week low of Rs 69.40 on 17 February 2016. The stock had outperformed the market over the past one month till 8 July 2016, surging 45.63% compared with Sensexs 0.39% rise. The scrip had also outperformed the market in past one quarter, advancing 44.21% as against Sensexs 9.94% rise.

The large-cap public sector bank has equity capital of Rs 392.72 crore. Face value per share is Rs 2.

The Reserve Bank of India (RBI) notified on Friday, 8 July 2016 that the aggregate foreign share holding by Foreign Institutional Investors (FIIs)/Registered Foreign Portfolios Investors (RFPIs)/Non Resident Indian (NRI)/Persons of Indian Origin (PIO)/Foreign Direct Investment (FDI)/American Depository Receipts (ADR)/Global Depository Receipts (GDR) under Portfolio Investment Scheme (PIS) in PNB has gone below the prescribed threshold caution limit stipulated under the extant FDI policy. Hence, the restrictions placed on the purchase of shares of PNB are withdrawn with immediate effect.

PNB reported net loss of Rs 5367.14 crore in Q4 March 2016 compared with net profit of Rs 306.56 crore in Q4 March 2015. Total income declined 1.3% to Rs 13276.19 crore in Q4 March 2016 over Q4 March 2015.

The Government of India held 62.08% stake in PNB (as per the shareholding pattern as on 30 June 2016).

Powered by Capital Market - Live News

Sun Pharma gains after launching ready-to-administer oncology solution
Jul 11,2016

The announcement was made before trading hours today, 11 July 2016.

Meanwhile, the BSE Sensex was up 388.78 points, or 1.43%, to 27,515.68.

On BSE, so far 14,000 shares were traded in the counter, compared with average daily volume of 5.55 lakh shares in the past one quarter. The stock hit a high of Rs 791 and a low of Rs 783.60 so far during the day. The stock hit a 52-week high of Rs 965.15 on 20 August 2015. The stock hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had outperformed the market over the past 30 days till 8 July 2016, rising 4.84% compared with 1.36% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, 4.10% as against Sensexs 9.94% rise.

The large-cap company has an equity capital of Rs 240.68 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries announced the roll-out of Gemcitabine InfuSMART in Europe. InfuSMART is a technology in which oncology products are developed in a Ready-To-Admimster (RTA) bag. Until now, compounding of oncology products was done at compounding centres or compounded in hospital pharmacies, an extra step before the medicine can be administered to patients. With the roll-out of Gemcitabine InfuSMART, Sun Pharma becomes worlds first pharmaceutical company to manufacture and launch a licensed RTA oncology product. This innovatively differentiated product will have a shelf life of two years. Over the next few months, Sun Pharma will launch Gemcitabine InfuSMART across Netherlands, UK, Spain, Germany, Italy & France.

Sun Pharma received regulatory approval to produce Gemcitabine InfuSMART in eight key stock keeping units (SKUs). The InfuSMART concept involves dose banding practice whereby, through agreement between prescribers and pharmacists, standardized doses of intravenous cytotoxic drugs are used for ranges (or bands) of doses calculated for individual patients. More InfuSMART oncology products are currently in Sun Pharmas pipeline to be rolled out in the future.

The launch of Gemcitabine InfuSMART offers Sun Pharma a definite first-mover advantage in Europe for cancer treatment. The Gemcitabine InfuSMART RTA infusion bag is developed at Sun Pharmas R&D centre in India, the company said.

Sun Pharmaceutical Industries (Sun Pharma) consolidated net profit rose 92.7% to Rs 1713.69 crore on 21.5% growth in net sales to Rs 7413.87 crore in Q4 March 2016 over Q4 March 2015.

Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

Manpasand Beverages scales record high after bulk deal
Jul 08,2016

Meanwhile, the BSE Sensex was down 74.80 points, or 0.27%, to 27,126.69

Bulk deal boosted volume on the Infosys scrip. On BSE, so far 14.92 lakh shares were traded in the counter, compared with average daily volume of 21,703 shares in the past one quarter. The stock hit a high of Rs 633 so far during the day, a record high for the scrip. The stock hit a low of Rs 577.55 so far during the day. The stock hit a 52-week low of Rs 286 on 9 July 2015. The stock had outperformed the market over the past 30 days till 7 July 2016, rising 15.36% compared with 0.67% rise in the Sensex. The scrip also outperformed the market in past one quarter, gaining 14.37% as against Sensexs 10.24% rise.

The small-cap company has an equity capital of Rs 50.05 crore. Face value per share is Rs 10.

Manpasand Beverages net profit rose 47.69% to Rs 25.55 crore on 90.96% rise in net sales to Rs 230.39 crore in Q4 March 2016 over Q4 March 2015.

Manpasand Beverages is a fruit drink manufacturer focusing on mango. Mango-based fruit drink, Mango Sip, is the flagship brand of the company, which is strategically aimed at customers in semi urban and rural markets. In addition, the company also sells fruit drink in apple flavor under the brand Apple Sip.

Powered by Capital Market - Live News

PFC gains as board to mull bonus issue
Jul 08,2016

The announcement was made during trading hours today, 8 July 2016.

Meanwhile, the BSE Sensex was down 62.21 points, or 0.23%, to 27,139.28.

On BSE, so far 8.46 lakh shares were traded in the counter, compared with average daily volume of 1.66 lakh shares in the past one quarter. The stock hit a high of Rs 196.25 and a low of Rs 181.80 so far during the day. The stock hit a 52-week high of Rs 270.60 on 21 July 2015. The stock hit a 52-week low of Rs 140.40 on 17 February 2016. The stock had outperformed the market over the past 30 days till 7 July 2016, rising 13.98% compared with 0.67% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 11.38% as against Sensexs 10.24% rise.

The large-cap company has an equity capital of Rs 1320.04 crore. Face value per share is Rs 10.

Power Finance Corporations (PFC) net profit declined 19.29% to Rs 1259.65 crore on 5.7% growth in total income to Rs 6786.99 crore in Q4 March 2016 over Q4 March 2015.

State-run PFCs main business is to provide finance to the power sector. Government of India (GoI) currently holds 67.8% stake in PFC (as per the shareholding pattern as on 31 March 2016).

Powered by Capital Market - Live News

Hatsun Agro Product spurts as board to allot bonus shares
Jul 08,2016

The announcement was made during trading hours today, 8 July 2016.

Meanwhile, the BSE Sensex was down 64.96 points, or 0.24%, to 27,136.53.

On BSE, so far 15,000 shares were traded in the counter, compared with average daily volume of 1,010 shares in the past one quarter. The stock hit a high of Rs 504.85 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 465 so far during the day. The stock hit a 52-week low of Rs 357.10 on 9 July 2015. The stock had underperformed the market over the past 30 days till 7 July 2016, falling 4.04% compared with 0.67% rise in the Sensex. The scrip had, however, outperformed the market in past one quarter, rising 10.66% as against Sensexs 10.24% rise.

The mid-cap company has an equity capital of Rs 10.87 crore. Face value per share is Re 1.

Hatsun Agro Product said that its board will allot bonus equity shares in the ratio of two new equity shares for every five existing equity shares.

The bonus issue was approved by the board at its meeting held on 27 May 2016. The issue was also approved by the companys shareholders via postal ballot process which was open between 31 May 2015 and 29 June 2016.

Later on 4 July 2016, the company announced that it fixed 14 July 2016 as the record date for the bonus issue.

Hatsun Agro Product will announce Q1 June 2016 results on 15 July 2016. The company reported net loss of Rs 16.79 crore in Q4 March 2016 as against net profit of Rs 8.66 crore in Q4 March 2015. Net sales rose 15.87% to Rs 892.05 crore in Q4 March 2016 over Q4 March 2015.

Hatsun Agro Product is Indias largest private sector dairy.

Powered by Capital Market - Live News